+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

MA 15.08 Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation



MA 15.08 Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation



Journal of Thoracic Oncology 12(11): S1863-S1864




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065015321

Download citation: RISBibTeXText

DOI: 10.1016/j.jtho.2017.09.590


Related references

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy 16(4): 383-390, 2016

Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment. Anticancer Research 38(9): 5231-5237, 2018

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer 126: 133-138, 2018

Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. Journal of Thoracic Disease 9(3): 470-473, 2017

P3.02b-026 Association of Egfr Exon 19 Deletion and Egfr-Tki treatment duration with Frequency of T790M Mutation in Egfr-Mutant Lung Cancer Patients. Journal of Thoracic Oncology 12(1): S1201-S1202, 2017

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA Oncology 1(7): 982-984, 2016

Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M. Plos One 9(12): E114000, 2015

EGFR -Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing. Journal of the National Comprehensive Cancer Network 15(10): 1188-1192, 2018

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report. Oncotargets and Therapy 12: 51-56, 2018

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis. Journal of Thoracic Oncology 12(9): E138-E139, 2019

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation. Oncotarget 7(28): 43315-43323, 2016

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer 127: 96-102, 2019

Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. Lung Cancer 2019, 2019

Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer. Clinical Lung Cancer 16(1): 46-50, 2015

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Translational Lung Cancer Research 3(3): 122-130, 2015